Pull to refresh
Logo
Slate Medicines merges with Fulcrum Therapeutics to reach Nasdaq

Slate Medicines merges with Fulcrum Therapeutics to reach Nasdaq

Money Moves

A failed drugmaker becomes the public listing for a $245 million bet on the next migraine target

August 17th, 2026: Slate and Fulcrum announce merger and $245M financing

Overview

Updated Aug 18

Fulcrum Therapeutics spent two years watching its two lead drugs fail. On August 17, 2026, the shell that remained agreed to merge with Slate Medicines, a privately held migraine startup, in an all-stock deal backed by a $245 million private placement.

The combined company keeps Slate's name, trades under the ticker 'SLTE,' and puts the new cash into one experimental antibody meant to prevent migraine by hitting a target current drugs miss. Slate's backers will own 95% of the result. Fulcrum's own shareholders keep just 5%, but get an estimated $270 million cash dividend paid out right before the deal closes.

Why it matters

The deal hands a next-generation migraine antibody a public listing and $245 million to challenge today's CGRP drugs, which don't work for everyone.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$245M
Private placement
Oversubscribed round led by Frazier Life Sciences, funding the company into 2029.
$270M
Special dividend to Fulcrum holders
Estimated cash payout to pre-merger Fulcrum stockholders just before closing, on top of their 5% stake in the combined company.
95%
Slate ownership of combined company
Pre-merger Fulcrum holders keep 5% in this reverse merger.
2029
Cash runway
The combined balance is expected to fund operations into 2029.
$130M
Slate Series A
Slate's February 2026 launch round, six months before the merger.
SLTE
New Nasdaq ticker
Fulcrum's 'FULC' becomes 'SLTE' when the deal closes.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

September 2024 August 2026

5 events Latest: August 17th, 2026 · 4 weeks ago
Tap a bar to jump to that date
  1. Slate and Fulcrum announce merger and $245M financing

    Latest Merger

    The two firms agree to an all-stock reverse merger paired with a $245 million placement. The combined company trades as 'SLTE' and is funded into 2029.

  2. Fulcrum drops its second drug

    Corporate

    Fulcrum discontinues pociredir for sickle cell disease after FDA safety concerns and opens a review of strategic options.

  3. Rival anti-PACAP drug posts positive data

    Clinical

    Lundbeck reports positive Phase 2b results for bocunebart, its own anti-PACAP migraine antibody, validating the target Slate is chasing.

  4. Slate Medicines launches

    Financing

    Slate emerges from RA Capital's incubator with a $130 million Series A to develop anti-PACAP antibodies for migraine prevention.

  5. Fulcrum's lead drug fails Phase 3

    Clinical

    Losmapimod misses its goals in a muscular dystrophy trial. Fulcrum's stock falls about 70% in a day, from $8.85 to $2.60.

Scenarios

1

Merger closes on schedule, SLTE starts trading

Likely Resolves by End of 2026

Discussed by: Company press release; BioPharma Dive; MedCity News

Both boards back the deal unanimously, and the $245 million is already committed. Fulcrum shareholders vote in the fourth quarter of 2026. With little pipeline left at Fulcrum, opposition is unlikely, and the reverse merger completes with the combined company trading as SLTE on Nasdaq.

2

SLTE-1009 delivers clean early human data

Possible Resolves by End of 2027

Discussed by: Slate Medicines; BioPharma Dive

Slate's antibody clears regulatory review in Australia and enters Phase 1. The company has guided to initial pharmacokinetic and safety data around mid-2027. A readout showing the drug is safe and behaves as designed would keep the runway-to-2029 thesis intact and open the door to efficacy trials.

3

Deal is terminated or repriced before closing

Unlikely Resolves by Jan 31, 2027

Discussed by: SEC merger risk disclosures

Reverse mergers can unravel if financing conditions slip, a shareholder vote fails, or diligence surfaces problems. A market downturn or a competitor setback in the anti-PACAP class could push investors to renegotiate the exchange ratio or walk. This is the low-probability path where the transaction does not complete as announced.

4

Lundbeck reaches Phase 3 first, defining the anti-PACAP class

Possible Resolves by End of 2027

Discussed by: NeurologyLive; Lundbeck disclosures

Lundbeck's bocunebart already has positive Phase 2b data and a multi-year head start on Slate's earlier-stage program. If Lundbeck starts a pivotal Phase 3 trial before Slate's drug leaves Phase 1, it would set the efficacy and safety bar for the whole anti-PACAP approach, shaping how investors value SLTE.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

May 2018

Aimovig and the CGRP migraine revolution (2018)

The FDA approved Aimovig (erenumab) from Amgen and Novartis, the first drug designed specifically to prevent migraine by blocking CGRP, a signaling molecule in the brain. Emgality, Ajovy, and Vyepti followed within two years.

Then

A class of injectable antibodies gave millions of patients a preventive option that older repurposed pills could not match.

Now

CGRP drugs grew into a multibillion-dollar market, but a large share of patients still respond poorly or not at all.

Why this matters now

Slate is betting the next gains come from PACAP, a separate pathway, for the patients CGRP drugs leave behind.

2020

Aduro Biotech's reverse merger into Chinook (2020)

Aduro Biotech, a public company whose cancer immunotherapy programs had stalled, merged with privately held Chinook Therapeutics, which developed kidney-disease drugs. Chinook took over the public listing and Aduro's cash.

Then

The deal gave Chinook a Nasdaq listing without a traditional IPO and refocused the company on new science.

Now

Novartis acquired Chinook in 2023 for up to $3.5 billion, one of the more successful biotech reverse mergers.

Why this matters now

It is the template for this deal: a failed public biotech becomes the vehicle for a well-funded private company's science.

2023–2024

Lundbeck's anti-PACAP proof of concept (2023)

Lundbeck's antibody Lu AG09222 cut migraine days versus placebo in a mid-stage trial, with results later published in the New England Journal of Medicine. It was the first clinical proof that blocking PACAP could prevent migraine.

Then

The data validated PACAP as a real drug target, distinct from CGRP.

Now

Lundbeck advanced the drug, now called bocunebart, into a larger Phase 2b program that read out positively in 2026.

Why this matters now

Slate's whole thesis rests on this mechanism; Lundbeck both proves it works and is the company to beat.

Sources

(9)